Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Background Tiotropium is an anticholinergic agent which has gained widespread
acceptance as a once daily maintenance therapy for symptoms and exacerbations of stable …

Objective To provide GRADE guidance for assessing risk of bias across an entire body of
evidence consequent on missing data for systematic reviews of both binary and continuous …

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global
morbidity and mortality, with a substantial economic impact. Recent changes in the Global …

Background Tiotropium+ olodaterol has demonstrated improvements beyond lung function
benefits in a large Phase III clinical program as a once-daily maintenance treatment for …

Background This study investigated the effects on 24-h lung function and lung volume of a
once-daily fixed-dose combination (FDC) of the long-acting muscarinic antagonist tiotropium …

Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-
dose combination of the long-acting β 2-agonist indacaterol and the long-acting muscarinic …

Background Tiotropium and long‐acting beta 2‐agonists (LABAs) are both accepted in the
routine management for people with stable chronic obstructive pulmonary disease (COPD) …

Adult-onset asthma and chronic obstructive pulmonary disease (COPD) are major public
health burdens. This review presents a comprehensive synopsis of their epidemiology …

Background Tiotropium and ipratropium bromide are both recognised treatments in the
management of people with stable chronic obstructive pulmonary disease (COPD). There …